GlassScriptPhysician profile
James H Chillcott
NPI 1134187107
$3,146.59
in general payments reported to CMS, 2019-2025
25 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $239 · 2021: $766 · 2022: $499 · 2023: $545 · 2024: $354 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $808.71 | 2021-2025 | Ubrelvy, Vraylar |
| Novo Nordisk INC | $606.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $577.54 | 2019-2025 | |
| Amgen INC. | $436.50 | 2019-2024 | Prolia, Evenity, Otezla |
| Abbott Laboratories | $149.05 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $96.40 | 2021-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $82.07 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $57.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $51.26 | 2019-2025 | Eliquis, Camzyos |
| Vivus LLC | $32.37 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.74 | 2021 | |
| Glaxosmithkline, LLC. | $24.70 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $19.56 | 2022 | |
| Eisai INC. | $17.79 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $15.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.56 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.56 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.99 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2019 | |
| Merck Sharp & Dohme LLC | $11.90 | 2020 | |
| Amarin Pharma, INC. | $11.59 | 2021 | |
| Allergan, INC. | $11.58 | 2019 | |
| Radius Health, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chillcott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.